文献速递肝病

急性肾脏病在肝硬化合并急性肾损伤患者中常见且与不良结局相关

Acute kidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury.
PubMed 文献 · J Hepatol · 2022-02-23

该研究基于美国全国性住院肝硬化合并急性肾损伤(AKI)患者队列(n=6,250),评估急性肾脏病(AKD)的发生率及结局。AKD发生率为32%,与90天和180天死亡风险升高独立相关,并与新发慢性肾脏病(CKD)独立相关。

要点

  • 住院肝硬化合并AKI患者中32%发生AKD。
  • AKD与90天和180天死亡风险升高独立相关。
  • AKD与新发CKD独立相关,发生率64.0% vs 30.7%。

核心结论

  • AKD在约1/3的住院肝硬化合并AKI患者中发生,并与更差的生存和新发CKD相关。
  • 作者认为针对AKD的干预可能改善肝硬化合并AKI患者的结局。

研究设计与样本

  • 基于美国Cerner-Health-Facts数据库2009年1月至2017年9月的全国性住院肝硬化合并AKI患者队列(n=6,250),随访180天。
  • AKI和AKD分别依据KDIGO和ADQI的AKD及肾脏恢复共识标准定义。
  • 采用竞争风险多变量模型分析AKD与主要结局(死亡)和次要结局(新发CKD)的独立关联。

主要发现

  • 队列中32%的患者发生AKD。
  • 调整显著混杂因素后,AKD患者90天死亡风险更高(sHR 1.37;95% CI 1.14-1.66;p=0.001),180天死亡风险亦更高(sHR 1.37;95% CI 1.14-1.64;p=0.001)。
  • 新发CKD总体发生率为37.5%;AKD患者新发CKD发生率64.0%,高于无AKD患者的30.7%(p<0.001)。
  • 调整混杂因素后,AKD与新发CKD独立相关(sHR 2.52;95% CI 2.01-3.15;p<0.001)。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute kidney disease (AKD) is the persistence of acute kidney injury (AKI) for up to 3 months, which is proposed to be the time-window where critical interventions can be initiated to alter downstream outcomes of AKI. In cirrhosis, AKD and its impact on outcomes have been scantly investigated. We aimed to define the incidence and outcomes associated with AKD in a nationwide US cohort of hospitalized patients with cirrhosis and AKI. METHODS: Hospitalized patients with cirrhosis and AKI in the Cerner-Health-Facts database from 1/2009-09/2017 (n = 6,250) were assessed for AKD and were followed-up for 180 days. AKI and AKD were defined based on KDIGO and ADQI AKD and renal recovery consensus criteria, respectively. The primary outcome measure was mortality, and the secondary outcome measure was de novo chronic kidney disease (CKD). Competing-risk multivariable models were used to determine the independent association of AKD with primary and secondary outcomes. RESULTS: AKD developed in 32% of our cohort. On multivariable competing-risk analysis adjusting for significant confounders, patients with AKD had higher risk of mortality at 90 (subdistribution hazard ratio [sHR] 1.37; 95% CI 1.14-1.66; p = 0.001) and 180 (sHR 1.37; 95% CI 1.14-1.64; p = 0.001) days. The incidence of de novo CKD was 37.5%: patients with AKD had higher rates of de novo CKD (64.0%) compared to patients without AKD (30.7%; p <0.001). After adjusting for confounders, AKD was independently associated with de novo CKD (sHR 2.52; 95% CI 2.01-3.15; p <0.001) on multivariable competing-risk analysis. CONCLUSIONS: AKD develops in 1 in 3 hospitalized patients with cirrhosis and AKI and it is associated with worse survival and de novo CKD. Interventions that target AKD may improve outcomes of patients with cirrhosis and AKI. LAY SUMMARY: In a nationwide US cohort of hospitalized patients with cirrhosis and acute kidney injury, acute kidney disease developed in 1 in 3 patients and was associated with worse survival and chronic kidney disease. Interventions that target acute kidney disease may improve outcomes of patients with cirrhosis and acute kidney injury.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Patidar KR, Naved MA, Grama A, et al. Acute kidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury. J Hepatol. 2022. PMID: 35217065. doi:10.1016/j.jhep.2022.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。